Friday, April 19, 2013

Theralase’s Innovative Anti-Cancer Technology Validated at Major International Conferences

Toronto, Ontario – April 19, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that its innovative Photo Dynamic Compound (PDC) technology has been accepted for presentation at two major international scientific conferences. Acceptance at these conferences validates the significance of the technology and its efficacy in the destruction of cancer cells in research performed by Theralase's internationally acclaimed scientists.

The efficacy of the anti-cancer Photo Dynamic Compound technology will be presented at LASER World of Photonics conference in Munich, Germany on May 15, 2013.

The effective destruction of bacteria using Theralase’s light activated Photo Dynamic Compound technology will be presented at Photonics North conference in Ottawa, Canada on June 3, 2013.

In further developments, Theralase’s Chief Scientific Officer, Dr. Arkady Mandel has been elected to the Editorial Board of Photonics & Lasers in Medicine (PLM) journal and chosen as issue editor of PLM for the Low Level Laser Therapy (LLLT) issue. PLM is an internationally peer-reviewed journal, which publishes clinical and scientific studies concerned with the clinical and scientific application of lasers and biophotonics in medicine for diagnostic and therapeutic purposes. PLM recently featured the clinical success of Theralase’s pivotal randomized placebo controlled clinical trial entitled, “Laser Therapy Applications for Osteoarthritis and Chronic Joint Pain.”

Roger Dumoulin-White, President and CEO of Theralase said, "I am pleased that Theralase’s scientific and clinical research has been recognized and acclaimed by two of the finest international scientific conferences and has been published in a peer reviewed medical journal. Theralase is committed to the early commercialization of its patented light activated Photo Dynamic Compounds in the areas of anti-cancer and anti-bacterial applications to generate substantial revenue increases for the Company. To accelerate this process, we are actively looking to collaborate with strategic partners to further develop our technologies and increase shareholder value. Theralase’s strong PDC pipeline has scientifically proven that our PDC technology is capable of consistently producing cell kill levels of 100%, even at very low concentrations, across a wide range of cancers and bacteria. In fact, our PDCs have been proven to be significantly more effective in destroying cancer cells and bacteria than currently FDA approved Photo Dynamic Compounds.”

About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.

 For further information please visit , regulatory filings may be viewed by visiting
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information
Roger Dumoulin-White                                                                     
President & CEO                    
416-699-LASE (5273) ext. 225                          

Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224 

Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 260

Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258   

No comments:

Post a Comment